Telomeres, the beginning(s) of the end. On the Nobel Prize in Physiology or Medicine awarded to Elizabeth H. Blackburn, Carol W. Greider, and Jack W. Szostak by Tusell, Laura
CONTRIBUTIONS to SCIENCE, 7 (2): 101–107 (2011)
Institut d’Estudis Catalans, Barcelona
DOI: 10.2436/20.7010.01.114  ISSN: 1575­6343 
www.cat-science.cat
The Nobel Prizes 2009
Resum.	El Premi Nobel de Fisiologia o Medicina 2009 ha guar­
donat Elizabeth H. Blackburn, Jack W. Szostak i Carol W. Grei­
der pels seus treballs en el camp dels telòmers i la telomerasa. 
Els telòmers són formats per seqüències curtes de DNA repeti­
des en tàndem, a les quals s’associen diverses proteïnes. 
Aquestes estructures nucleoproteiques es troben en els ex­
trems dels cromosomes i són vitals per a mantenir la integritat 
del genoma, ja que eviten que els cromosomes es fusionin els 
uns amb els altres. A més de la funció essencial de protecció, 
els telòmers també tenen un paper fonamental en la replicació 
completa dels extrems cromosòmics. La longitud telomèrica 
es manté gràcies a l’enzim telomerasa, un complex constituït 
per RNA i proteïna que és actiu en cèl·lules germinals i embrio­
nàries, però inactiu en la major part de cèl·lules somàtiques en 
humans. L’absència de telomerasa en cèl·lules proliferants 
provoca que els telòmers s’escurcin amb les divisions cel·lulars 
successives. Quan els telòmers s’escurcen per sota d’una lon­
gitud crítica, les cèl·lules aturen la proliferació i entren en una 
fase de senescència, estat irreversible d’aturada permanent, o 
bé activen mecanismes de mort cel·lular programada. Malgrat 
això, algunes cèl·lules poden ser capaces de continuar prolife­
rant, fet que produeix la desprotecció dels extrems cromosò­
mics. La inestabilitat cromosòmica massiva associada a 
aquest estat podria ser el mecanisme pel qual alguna cèl·lula 
adquireix determinades alteracions genètiques necessàries 
per a la transformació maligna.
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Abstract.	The 2009 Nobel Prize for Physiology and Medicine 
was awarded to Elizabeth H. Blackburn, Jack W. Szostak, and 
Carol W. Greider for their work on telomeres and telomerase. 
Telomeres are formed by short DNA sequences repeated in 
tandem and associated with different proteins. These struc­
tures, which are found at the ends of chromosomes, are crucial 
for maintaining genomic stability by preventing chromosomes 
from joining with one another. In addition to this essential pro­
tective function, telomeres play a vital role in complete DNA 
end replication. Telomere length is maintained by the enzyme 
telomerase—a complex made up of RNA and proteins that in 
humans is active is germinal and embryonic cells but inactive in 
somatic cells. The absence of telomerase in proliferating cells 
leads their telomeres to shorten with successive cell divisions. 
Eventually, the telomeres reach a critically short length that in 
turn causes massive chromosome instability. This may be the 
mechanism through which a cell acquires the genetic alterna­
tions needed to become malignant. Normally, however, below 
this critical length, the cells stop dividing and either enter a 
phase of senescence or an irreversible state of arrest, or mech­
anisms are activated for programmed cell death. However, 
some cells that also carry alterations in cell cycle checkpoint 
proteins continue replicating, giving rise to uncapped chromo­
some ends and thus to a malignant potential. 
Keywords:	telomeres ∙ telomerase ∙	Tetrahymena 
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∙ carcinogenesis 
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The 2009 Nobel Prize for Physiology and Medicine was award-
ed to Elizabeth H. Blackburn, Jack W. Szostak, and Carol W. 
Greider for their work on telomeres and telomerase (Fig. 1). In 
1938,  Herman  Müller  noted  the  existence  of  a  specialized 
structure at the natural ends of chromosomes as he was ana-
lyzing the chromosomal anomalies induced by X-rays in the fly 
Drosophila. In this study, Müller found that the natural ends of 
the chromosomes were never involved in the chromosomal re-
organizations that appeared, such as inversions, fusions, and 
translocations  [16]. Based on  these observations, Müller de-
duced that the ends of chromosomes must have a specialized 
structure that protected them from fusion phenomena. Around 
the  same  time,  Barbara McClintock  reached  similar  conclu-
sions after analyzing the behavior of dicentric chromosomes in 
the corn plant Zea mays. During mitosis, the displacement of 
two  centromeres  from  a  single  chromatid  towards  opposite 
poles leads to the formation of a structure known as an ana-
phase bridge. Finally, the tension triggered causes the bridge 
to break, and the chromosome ends generated tend to fuse 
once again,  leading to a breakage-fusion-bridge (BFB) cycle. 
McClintock determined that  the natural ends of  the chromo-
somes never participated in the formation of these fusions [15]. 
Therefore, both observations evidenced the existence of struc-
tural and functional properties on the natural ends of chromo-
somes that were unlike the double-strand breaks of DNA and 
protected  the  structures  from  chrmosomal  fusion,  degrada-
tion, and recombination.
The structure of telomere
However, telomeres were ignored until the 1970s, when Elisa-
beth Blackburn joined Joseph G. Gall’s research group at Yale 
University, New Haven,  to sequence  the ends of  linear mini-
chromosomes  in  the protozoan Tetrahymena thermophila.  In 
1978, Blackburn and Gall published their findings that the tel-
omeres of the protozoa were made up of G-rich DNA stretches 
repeated in tandem [2]. Since then, the telomeres of numerous 
species have been described, and it has become clear that tel-
omere sequences are highly conserved in the different organ-
isms studied. Telomere DNA in eukaryotic organisms consists 
of a double-strand region with a short sequence rich  in G-C 
tandem repeats and a 3′ single-strand G-rich overhang. In ver-
tebrates, these repeats consist of of six nucleotides (TTAGGG) n 
but  the  length of double-strand  telomere DNA and of  the 3′ 
single-strand overhang differ among different species. In Homo 
sapiens, telomere length fluctuates between 5 and 15 kb, while 
in Mus musculus it is 40–60 kb (Fig. 2). 
Initially, the telomere was seen as a linear structure; this tra-
ditional view was abandoned in 1999, after studies by Griffith 
and collaborators [11], who showed in vitro that incubation of a 
telomeric  DNA  sequence  with  the  telomere  protein  TRF2 
(TTAGGG Repeat Factor 2) resulted in a change in its structure 
from linear to loop-shaped. This loop structure, which the au-
thors named the t-loop, was produced through folding of the 3′ 
single-strand overhang over the double helix of telomere repe-
titions  located  further  back,  thus  protecting  the  ends  of  the 
chromosomes.  Since  then  numerous  telomere-associated 
proteins have been described. The shelterin protein complex is 
made up of six proteins (TRF1, TRF2, POT1, TIN2, TPP1, and 
Rap1) that maintain telomeres during all phases of the cell cy-
cle and serve no other function anywhere else inside the nu-
cleus [18]. These proteins are extremely  important  in forming 
and preserving a sealed structure on the chromosome ends, in 
inhibiting  DNA  repair  processes,  and  in  regulating  telomere 
length. Moreover, there is also a group of less abundant pro-
teins in the telomere that contribute to protecting the chromo-
some ends, are only temporarily associated with the telomeres, 
and are known to carry out non-telomere functions both inside 
and outside the nucleus. Many of these proteins are involved in 
DNA-damage signaling, DNA repair and replication, and chro-
matin structure.
The earliest studies
While Elisabeth Blackburn was studying the ends of Tetrahy-
mena  chromosomes,  Jack  Szostak  was  studying  gene  re-
combination in the yeast Saccharomyces cerevisiae at the Sid-
ney Farber Cancer Institute in Boston, where he had his own 
laboratory. In his studies, he observed that when circular plas-
mids were introduced inside yeast cells, instead of integrating 
Fig. 1. From  left  to  right, Elizabeth H. Blackburn, Carol W. Greider, 
and Jack W. Szostak. © The Nobel Foundation. Photos: Ulla Montan. 
Fig. 2.  Human chromosomes  (blue)  in metaphase hybridized with a 
centromere probe (green) and a telomere probe (red).
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inside the yeast chromosomes they basically remained extra­
chromosomal, leading to a low recombination frequency of the 
two genomes. However, if the plasmids were made linear by 
cutting them with a restriction enzyme, the frequency of re­
combination phenomena increased and the plasmids that did 
not integrate into the yeast genome become degraded.
Blackburn and Szostak met in 1980 at the Gordon Research 
Conference on Nucleic Acids, and decided then and there to 
embark upon a collaborative project with the goal of ascertaining 
whether the telomeres of Tetrahymena could stabilize the ends 
of linearized plasmids. After introducing these linear plasmids 
capped with Tetrahymena telomeres (TTGGGG)n into yeast 
cells, they found that the linear shape remained, without recom­
bining or degrading [22]. These experiments paved the way for 
artificial chromosomes and enabled the researchers to deter­
mine that telomeres operated in a variety of phylogenetic king­
doms. Subsequent studies led to the identification of the specific 
sequence of yeast telomeres. However, the most curious obser­
vation of all was that Tetrahymena telomeres placed inside yeast 
cells elongate and become more heterogeneous. An exhaustive 
study of these plasmids by Shampay and collaborators [20] de­
cisively revealed the mechanism underlying the elongation of the 
chromosomes ends. When linearized plasmids stabilized with 
the Tetrahymena telomeres (TTGGGG) were introduced into 
yeast, additional telomere repetitions took place. This addition 
was easy to detect since the new repetitions had the specific 
sequence of yeast telomeres (TG1–3). Two different models were 
proposed to explain this phenomenon. The first invoked the 
presence of a terminal transferase capable of adding new tel­
omere repetitions, and the second a gene recombination proc­
ess.
Maintenance	of	telomere	length
In 1984, Carol Greider joined the Blackburn laboratory and be­
gan to search for the cellular enzyme capable of adding tel­
omere repetitions to the ends of chromosomes. Her studies 
consisted of incubating synthetic oligonucleotides of different 
sequences with protein extracts from Tetrahymena. On Christ­
mas Eve 1984, these experiments finally revealed the existence 
of a specific enzyme responsible for maintaining telomere 
length. Only the oligonucleotides that had the Tetrahymena or 
the yeast telomere sequence were elongated; there was no 
new addition of telomeric sequences at the ends of DNA frag­
ments with other sequence compositions [8]. These results 
confirmed the existence of an enzyme capable of elongating 
the ends of chromosomes, which was named telomerase. Lat­
er, the same researchers determined that it was not a conven­
tional enzyme but a ribonucleoprotein [9]. Specifically, telomer­
ase consists of two main subunits, an RNA component (TERC) 
containing a sequence complementary to the telomeric over­
hang, and a protein component with reverse transcriptase ac­
tivity (TERT), as well as numerous additional proteins. Telomer­
ase promotes telomere elongation by copying the nucleotides 
of the template RNA at the overhanging 3' end of the chromo­
some, a function carried out by TERT, and afterwards the cell’s 
conventional replication machinery copies the nucleotides at 
the 5' end [10].
These discoveries were crucial in understanding the events 
occurring at the ends of chromosomes. Studies subsequent 
to the discovery of telomerase revealed the presence of mu­
tant yeast cells whose telomere length shortened with cell di­
visions, called EST1 (even shorter telomeres) [14]. These 
yeast cells showed an increased rate of chromosomal loss 
with successive generations; additionally, associated with 
progressive shortening of the telomeres was the gradual ap­
pearance of a senescent phenotype. Similar results were ob­
tained by the Blackburn group in Tetrahymena when muta­
tions were generated in the telomerase RNA template, 
suggesting that telomeres are important to genome stability 
and to cell viability [24].
In fact, back in 1973 Alexei Olovnikov had postulated that, 
given the characteristics of DNA replication, DNA polymerase 
was incapable of copying the 3' ends of linear DNA molecules, 
which led to shortening of the telomere in each cell division cy­
cle. DNA polymerase can only extend primers from their free 3' 
OH end, synthesizing DNA in the 5' to 3' direction. Given that 
DNA is made up of two anti­parallel strands, one of them, the 
leading strand, is synthesized continuously in the same direc­
tion as the replication fork proceeds, and the other, the lagging 
strand, discontinuously in the opposite direction through the 
extension of RNA primers (Okazaki fragments) by the action of 
DNA polymerase. The RNA primers are replaced by DNA as 
the Okazaki fragments grow, but elimination of the primer on 
the 5' end of the chromosome results in the shortening of the 
newly synthesized strand. Today we know that in addition to 
the phenomenon of the replication terminus, there is also ac­
tive deterioration of the chromosome ends to generate an 
overhang long enough to form the t­loop structure. In the ab­
sence of a compensatory mechanism, this results in a loss of 
50–200 bp in the telomere track after each round of replication.
Therefore, when there is no telomerase activity in the cells, 
the chromosomes shorten their telomeres, as is the case in 
vitro or during the aging process of an organism. In humans, 
chromosomal shortening occurs in the majority of somatic 
cells, since the enzyme telomerase is inactive; by contrast, in 
germinal line cells, stem cells, proliferating somatic cells, and 
tumor cells the enzyme is active, compensating for the loss of 
nucleotides during DNA replication.
Telomeres	and	the	potential	of	cell	proliferation
For many years it was thought that the cells of pluricellular organ­
isms had the capacity to proliferate indefinitely. However, this 
view changed radically in 1965, when Hayflick observed that hu­
man fibroblasts in culture underwent a finite number of divisions 
before entering a non­proliferative state. This state, known as 
replicative senescence or the Hayflick limit, is characterized by a 
permanent cellular arrest in the G1 phase of the cell cycle, which 
enables cells to remain metabolically active and viable for long 
periods of time. These observations gave rise to the hypothesis 
of the existence of a biological clock that counts the number of 
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divisions a cell is able to undergo, and is likewise capable of ar­
resting cell growth after a certain number of divisions.
It was not until the 1990s that replicative senescence was 
associated with telomeres, after Harley, Futcher, and Greider 
[12] demonstrated telomere shortening after each round of cell 
division that in human fibroblasts, as predicted in the DNA rep­
lication models proposed by Olovnikov [17] and Watson [23]. 
Therefore, it was confirmed that when telomeres shorten to a 
critical length, cells stop proliferating and become senescent. 
Expression of the constitutive form human TERT (hTERT) in 
pre­senescent fibroblasts, lymphocytes, epithelial cells, and 
other cell types, by contrast, can extend the proliferative ca­
pacity of the cells, thus confirming the role of telomeres in the 
replicative senescence of cells [4]. We should point out that 
senescence can also be induced by factors other than telom­
eres, such as viral infection or oxidative stress.
Today we know that the true cause of the entry into senes­
cence is not the reaching of a critical telomere length but the 
loss of the t­loop. This vulnerability of the telomere occurs fol­
lowing the loss of repetitions of telomeric DNA or of proteins 
associated with the t­loop. Loss of the telomere’s structure 
eliminates the ability of the normal cellular repair machinery to 
distinguish between natural and broken chromosome ends. In­
deed, alterations in telomere structure following the overex­
pression of a negative dominant allele of TRF2 lead to the acti­
vation of ATM and ATR, two proteins that signal specifically 
damaged DNA, which in turn activate cellular repair enzymes. 
This sequence of events is supported by the observation that 
proteins recognizing and/or repairing DNA damage accumu­
late in the vicinity of the excessively short telomeres of senes­
cent human fibroblasts [5]. These findings suggest that short or 
dysfunctional telomeres activate the same type of response as 
occurs when DNA is damaged directly, and that senescence 
involves mechanisms similar to those operating in response to 
DNA damage.
Therefore, the successive erosion of telomeres in each cell 
division cycle leads to the loss of the t­loop and consequently 
the capacity of the telomeres to protect the chromosome ends. 
This eventually culminates in the loss of genetic material and an 
increase in chromosomal instability, unless a cellular response 
to the damaged DNA occurs, such as cell cycle arrest or pro­
grammed cell death, also known as apoptosis. For this reason, 
when telomeres reach a critical length after many rounds of di­
visions, the cells permanently arrest in the G1 phase of the cell 
cycle in response to several signals: the actions of DNA dam­
age repair proteins [21], activation of the cell cycle control pro­
teins Rb and p53, and the expression of the Cdk protein inhibi­
tors p16INK4a and p21. For the majority of cells, senescence 
represents an irreversible state of permanent arrest, but they 
are still both metabolically active and viable.
The	aging	organism
Senescent cells are known to accumulate in the tissues of eld­
erly individuals. Thus, while definitive evidence is lacking, it ap­
pears that the accumulation of viable, non­proliferating cells 
compromises tissue functionality and contributes to the differ­
ent pathologies associated with aging. Indeed, the role of tel­
omere homeostasis and cell senescence in the aging organism 
is backed by studies relating donor age and shortened telom­
eres in highly proliferating tissues, such as lymphocytes, mus­
cle cells, endothelial cells, lenticular epithelial cells, and adreno­
cortical cells, and the lower in­vitro proliferative capacity of cells 
from patients with premature aging syndromes (progeria), in­
cluding Werner syndrome, Bloom syndrome, Down syndrome, 
and Hutchinson­Gilford progeria syndrome. Studies of those 
patients have provided the most convincing data relating hu­
man aging and telomere dysfunction. Surprisingly, the cells of 
these individuals show alterations in telomere metabolism and 
telomeres that are much shorter than those of cells from con­
trol populations. Many of the progeria syndromes are caused 
by mutations in the genes encoding TERT or TERC or in those 
encoding proteins that interact with telomeres. Congenital dys­
keratosis was the first human illness whose pathogenesis could 
be attributed to mutations in telomerase components. These 
patients suffer from alopecia (hair loss), premature gray hair, 
tooth loss, osteoporosis, ungual dystrophies, defective skin pig­
mentation, and deterioration of the immune system. These 
symptoms are similar to what occurs in the normal aging proc­
ess in humans and are also seen in mice deficient in telomerase.
The generation of mTerc-/- mice, deficient in telomerase 
RNA [3], enabled researchers to demonstrate the impact ex­
erted by a given telomere length on both the cellular level and 
the organism as a whole. The mutant mice exhibit a gradual 
reduction in the length of their telomeres during and over suc­
cessive rounds of cell division, as is the case in the somatic 
cells of aging humans. Early generations of these animals do 
not show an obviously pathological phenotype, most likely be­
cause their cells still have sufficiently long telomeres. However, 
in later generations there are defects in highly proliferative tis­
sues, such as the hematopoietic system, reproductive organs, 
and the intestinal epithelium, in addition to signs of premature 
aging. These observations imply that a minimum telomere 
length is needed to maintain the functional integrity of tissues 
and that the protection and maintenance of telomere length are 
important factors in controlling cell life­span; however, when 
discussing the aging process, we must also bear in mind that it 
is a highly complex process that is influenced not only by tel­
omere length but also by many other regulatory factors.
Telomeres,	chromosomal	instability,	and	
carcinogenesis
The loss of telomere function in mTerc-/- mice is also associat­
ed with the formation of chromosomal fusions and the genera­
tion of aneuploidy. Telomeres that have become dysfunctional 
because of excessive shortening are recognized by the same 
cell mechanisms that respond to DNA damage but are incor­
rectly repaired by these mechanisms, leading to chromosomes 
with two centromeres. These dicentric chromosomes, as Mc­
Clintock postulated, can give rise to an endless chain of BFB 
cycles, generating new chromosomal anomalies with each cell 
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division. Thus, over time, cells with a high proliferative capacity 
will accumulate extensive chromosomal instability, thus acti­
vating p53, which triggers programmed cell death. In fact, the 
dysfunction of highly proliferative tissues in mTerc-/- mice is as­
sociated with high rates of apoptosis. 
In contrast to the relationship between excessive telomere 
shortening and senescence or apoptosis, excessive telomer­
ase activity is related to malignancy. In fact, 85% of human 
cancers show telomerase activity. Given this fascinating con­
nection, telomerase­deficient mice would be a good model to 
determine the relationship between telomere length, telomer­
ase, and cancer. In fact, experiments in later generation (G4–
G6) mTerc-/- mice have shown that the absence of telomerase 
suppresses tumor progression. This tumor­suppressing phe­
notype of excessively short telomeres is related to the activa­
tion of p53. In mTerc-/- mice in advanced generations, there is a 
decline in tumor formation due to the loss of cell viability—cou­
pled with a rise in p53­mediated apoptosis—which is associ­
ated with telomere dysfunction. Likewise, studies of mice defi­
cient in both telomerase and other cancer­related proteins, 
such as APCMIN, INK4a/Arf­/­, ATM­/­, and Alb­uPA­/­, also de­
tected a reduction in carcinogenesis in these animals.
Specifically, experiments conducted with double­mutant in 
mTerc-/-/ApcMIN mice enabled researchers to associate tel­
omere dysfunction with incipient stages of neoplasia. Even 
though the initial number of neoplastic lesions was higher in 
mTerc-/-/ApcMIN mice than in ApcMIN mice, the growth and pro­
gression of adenomas was significantly suppressed in the dou­
ble mutants. These studies showed that an initial telomere dys­
function is necessary to promote chromosomal instability 
capable of generating a preneoplastic lesion; however, later, to 
allow for tumor growth, telomerase must be reactivated in or­
der to stabilize the genome [19]. If this is not the case, then the 
chromosomal instability is unsustainable and most of the cells 
die through apoptosis. These results are consistent with very 
low or nonexistent telomerase activity in the majority of incipi­
ent neoplasias in humans, while the progression to a state of 
malignancy is associated with high telomerase activity.
Important insights into an association between telomere 
dysfunction and human epithelial carcinogenesis have come 
from studies in which mTerc-/- mice were crossed with mice 
deficient in p53 [1]. Telomere erosion triggers a damage signal 
in p53­dependent DNA; thus, in the presence of functional 
p53, short telomeres promote apoptosis or the G1­phase ar­
rest of cells. In later generations of mTerc-/-/p53-/- mice, the 
loss of p53 recapitulates many of the symptoms caused by 
telomere dysfunction, such as the apoptosis of germinal cells, 
even though they have short telomeres. The recovery of these 
cells with short telomeres and a higher proliferative activity re­
sults in greater genomic instability, the appearance of tumors 
at early ages, and a decline in animal survival. However, the 
most important observation in this study was the appearance 
of a small proportion of carcinomas, which had not been found 
in mTerc-/-/p53+/+ mice. These observations suggest that the 
premature death of mTerc-/-/p53+/+ mice from lymphoid or 
mesenchymal cancers masked the impact of telomere dys­
function on epithelial carcinogenesis. In p53 haploinsufficient 
mice, mTerc-/-/p53+/-, there was an increased incidence of tu­
mors and a radical change in their spectrum, evidenced by a 
shift from lymphoproliferative to carcinomas in old vs. young 
mice. Moreover, the murine carcinomas showed complex 
structural chromosomal anomalies similar to those found in 
human carcinomas. These results along with the fact that hu­
man neoplastic cells display short telomeres and complex 
chromosomal anomalies led to speculations that telomere 
dysfunction is a risk factor that contributes to tumorigenesis. 
Accordingly, a model was proposed in which telomere dys­
function coupled with deficiencies in cell cycle checkpoints is 
responsible for the appearance of carcinomas in the adult hu­
man population [6].
Model	of	human	epithelial	carcinogenesis
The majority of cancers in the adult human population are epi­
thelial in origin. Indeed, epithelial tumors account for 83.6% of 
adult neoplasias and the incidence rises with age. As dis­
cussed above, most carcinomas show chromosomal instabili­
ty, manifested as complex chromosomal anomalies. According 
to the epithelial carcinogenesis model, chromosomal instability 
in proliferative epithelial cells depends on the telomere shorten­
ing that occurs as cells divide, coupled with deficiencies in cell 
cycle checkpoints.
Epithelial cells proliferate throughout the human lifespan to 
regenerate the epithelium. However, these cells have no telom­
erase activity, such that their telomeres become shorter as the 
individual ages. When the telomeres reach a critically short 
length, mechanisms are activated to limit cell division, such 
that cell cycle progression is halted (replicative senescence). If 
these mechanisms are damaged, the cells may continue to 
proliferate, with even further shortening of their telomeres. This 
leads to a loss in telomere structure and thus of the cells’ ability 
to distinguish the natural chromosome ends from double­
strand breaks in DNA. Consequently, the cellular repair ma­
chinery is activated, and the unprotected chromosome ends 
are thereby fused. These telomere­telomere fusions give rise to 
dicentric chromosomes with two centromeres and thus poten­
tially to a genomic instability in successive cell divisions through 
the advent of BFB cycles. This massive chromosomal instabili­
ty ends in a phase of cell crisis, characterized by the presence 
of very short telomeres, telomere fusions, anaphase bridges, 
and a high rate of apoptosis. Even though most cells in this 
crisis stage will die, a very low percentage survive and become 
immortalized through the activation of mechanisms capable of 
maintaining telomere length, such as telomerase reactivation.
Chromosome stabilization through telomerase or the ALT 
(alternative lengthening of telomeres) mechanism reduces 
chromosomal instability at the cost of providing the tumor with 
unlimited proliferative capacity. For all of these reasons, de­
spite the barriers to cell proliferation posed by the crisis stage 
and replicative senescence, the massive chromosomal insta­
bility associated with crisis might be the mechanism through 
which some cells acquire the genetic alterations needed to be­
come malignant [21].
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Therefore, telomere shortening and the activation of telom­
erase can act as either tumor suppressors or oncogenes, de­
pending on when they take place and their genetic context. On 
the one hand, the loss in telomere repetitions in an intact cellu­
lar environment serves as a tumor­suppressing mechanism, 
limits cell proliferation, and causes senescence or apoptosis. 
However, the loss in telomere structure in an environment defi­
cient in genes that act as cell cycle checkpoints leads to tel­
omere instability due to the absence of telomerase and fosters 
the onset of malignant transformation (Fig. 3).
Pro-	and	anti-telomerase	treatments
Given the close relationship between telomerase, aging, and 
cancer, a number of studies have recently been conducted to 
ascertain whether therapies directed at the overexpression or 
inhibition of telomerase have any effect on the regeneration of 
tissues damaged during aging or can prevent/inhibit tumor 
growth. The stimulation or reactivation of telomerase would be 
expected to prevent aging in addition to providing a therapeutic 
strategy for telomere phenotype syndromes. However, it is still 
not clear whether an increase in telomerase activity is sufficient 
to prevent symptoms of aging. An improvement in tissue gener­
ation has been shown in genetically modified K5­Tert mice, 
which overexpress telomere activity in basal keratinocytes and 
stem cells of stratified epithelia [7]. The increase in telomere ac­
tivity reduced both the rate of atrophy in the testicles, uterus, and 
ovaries of these mice, and renal dysfunctions in elderly mice. 
Moreover, the life expectancy of the genetically modified mice 
was longer than that of the control group. By contrast, when K5­
Tert mice were treated with chemical carcinogens they had a 
higher mortality from cancer at advanced ages, suggesting the 
cooperation of other genetic anomalies over the lifetime of the 
mice, with an increase in telomerase playing a role in the genesis 
of neoplasia. These studies therefore suggest certain potential 
risks in gene therapies involving telomerase overexpression. At 
the same time, evidence that dysfunctional telomeres can acti­
vate both senescence and apoptosis, thus blocking tumorigen­
esis in different tissues, points to potential therapeutic applica­
tions of molecules with anti­telomerase capacity. Currently, 
several compounds have been shown to act on telomerase: 
those that directly inhibit the enzyme or target the proteins in the 
shelterin complex, and vaccines that stimulate the immune sys­
tem to attack cells expressing the telomerase antigen.
Numerous in vitro studies have demonstrated that the treat­
ment of different tumor cell lines with telomerase inhibitors 
leads to a shortening of the telomere and subsequently triggers 
inhibition of the cells’ proliferative potential. Furthermore, the 
treatment of tumor cells in immunocompromised mice inhibits 
tumor growth. Similarly, the administration of telomerase in­
hibitors to mice xenotransplanted with breast cancer cells was 
effective in preventing lung metastasis. These results with hu­
man cells in vitro and murine models in vivo show that such 
treatments can be highly effective in lowering tumor growth. 
Today, numerous anti­telomerase treatments are currently be­
ing tested in clinical trials (phase I, II, and III). Given the preva­
lence of high telomerase activity and/or the presence of short 
telomeres in multiple types of tumors compared to normal tis­
sue, targeting telomerase would seem to be a reasonable ap­
proach to the treatment of a wide range of cancers.
Brief	biography	of	the	Nobel	Prize	winners
Elizabeth	H.	Blackburn (Hobart, Tasmania, Australia, 1948) 
was born into a family of doctors. She moved from Tasmania to 
Melbourne (Victoria) in 1957, earning her Bachelor’s (1970) and 
her Master’s (1972) degrees from the University of Melbourne 
and her doctorate (1975) from Cambridge University (UK). After 
working as a postdoctoral fellow at Yale (1975–1977), she 
went to the University of California at Berkeley in 1978 and has 
Fig.	 3. The relationship between telomeres 
and telomerase and aging and cancer depends 
on an environment that is, respectively, profi­
cient or deficient in cell cycle checkpoints.
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worked at the University of California at San Francisco since 
1990. Although she is primarily known for her studies on telom­
eres and the role of telomerase, her name was also catapulted 
into the newspaper headlines in February 2004 when she was 
removed from the President’s Council on Bioethics, presuma­
bly due to disagreements with George W. Bush’s administra­
tion over the issue of research into totipotential cells derived 
from human embryos.
Carol	W.	Greider (Davis, USA, 1961) graduated with a Bach­
elor’s degree in Biology from the University of California at Santa 
Barbara in 1983. In 1984, she began her doctoral studies with 
Blackburn at Berkeley, in the field of telomere protection. Using 
the model ciliated protozoa Tetrahymena, Greider and Black­
burn identified the activity of the enzyme telomerase, directing 
the controlled regeneration of chromosome ends. After the pub­
lication of an important article [8] in the journal Cell (1985), she 
finished her thesis in 1987. After completing her postdoctoral 
fellowships, Greider joined the Cold Spring Harbor Laboratory 
(Long Island, New York), with a joint appointment in 1997 at 
Johns Hopkins University. Her laboratory has primarily pursued 
avenues of research derived from her doctoral dissertation.
Jack	W.	Szostak (London, UK, 1952) graduated with a Bach­
elor’s degree in Biology from McGill University in 1971. He 
earned his doctorate at Cornell University and then permanently 
moved to Harvard Medical School. His laboratory is part of the 
Howard Hughes Medical Institute. His career has been linked to 
the field of genetic recombination and to studies on the proc­
esses that govern eukaryotic chromosomes, such as telomere 
dynamics (shortening and elongation, protection, and destruc­
tion). These studies helped him to design the first yeast artificial 
chromosomes (YACs), which have become fundamental tools in 
the manipulation of long DNA fragments, used in the compre­
hensive human genome mapping project completed during last 
decade. More recently, Szostak, has pursued studies on artificial 
chromosomes with the intention of generating ‘artificial cells,’ a 
process that could provide information on how the first cells 
emerged from the first organic compounds on primeval Earth.
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